At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 120 enrolled
Drug / intervention
AbobotulinumtoxinAbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Interventional Study to Evaluate Subject Satisfaction of AbobutulinumtoxinA Treatments in Moderate to Severe Glabellar Lines
In Brief
A Phase 4 clinical trial evaluating AbobotulinumtoxinA for Glabellar Frown Lines. Completed, enrolled 120 participants across 6 sites.
Detailed Summary
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionNov 2019
Study CompletionDec 2019
TodayJul 2026
First PostedSep 27, 2018
Enrollment StartOct 2, 2018
Primary CompletionNov 7, 2019
Study CompletionDec 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago
Interventions
AbobotulinumtoxinAbiological
AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6